Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages

Ebrahimiyan, Hamidreza; Tamimi, Amirhossein; Shokoohian, Bahareh; Minaei, Neda; Memarnejadian, Arash; Hassan, Moustapha; Vosough, Massoud

doi:10.1016/j.intimp.2022.108587

Cited by 31 publications

(12 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These CAR NK cells have been equally as effective as CARs with T cell internal signaling domains in ALL, osteosarcoma, and prostate cancer [ 88 , 89 ]. CAR NK cells are advantageous because adoptive cell transfers do not induce GvHD, and HLA matching is not required [ 90 , 91 , 92 ]. This allows for the potential of an off-the-shelf treatment option.…”

Section: Car Nk Cellsmentioning

confidence: 99%

“…While NK cells with HLA-mismatching may not induce GvHD, the effectiveness of HLA-mismatching is in discussion and may be limited by the rejection of HLA-mismatched NK cells, or in contrast, may enhance the treatment as HLA mismatched cancer cells are more readily recognized by donor NK cells [ 93 , 94 ]. Additionally, when compared to CAR T cells, CAR NK cells pose less of a threat in terms of CRS and neurotoxicity, making them a safer option than current CAR T cell therapies [ 90 , 92 ]. NK cells have also been shown to develop a subset of memory or memory-like cells that have been utilized in some cancer immunotherapy strategies and may provide an additional benefit in the creation of CAR NK cell therapies [ 95 , 96 , 97 ].…”

Section: Car Nk Cellsmentioning

confidence: 99%

“…Although NK cells participate in proinflammatory signaling, the cytokines released by NK cells are different than the release of T cells and do not elicit the same overactivation present in CRS. Additionally, NK cells in contrast to T cells can be obtained from allogeneic sources without fear of GvHD when not in a transplant setting [ 90 , 92 , 103 , 110 , 111 , 112 , 113 ].…”

Section: Car Nk Cellsmentioning

confidence: 99%

See 2 more Smart Citations

Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer

et al. 2022

View full text Add to dashboard Cite

For nearly three decades, chimeric antigen receptors (CARs) have captivated the interest of researchers seeking to find novel immunotherapies to treat cancer. CARs were first designed to work with T cells, and the first CAR T cell therapy was approved to treat B cell lymphoma in 2017. Recent advancements in CAR technology have led to the development of modified CARs, including multi-specific CARs and logic gated CARs. Other immune cell types, including natural killer (NK) cells and macrophages, have also been engineered to express CARs to treat cancer. Additionally, CAR technology has been adapted in novel approaches to treating autoimmune disease and other conditions and diseases. In this article, we review these recent advancements in alternative CAR therapies and design, as well as their mechanisms of action, challenges in application, and potential future directions.

show abstract

Section: Car Nk Cellsmentioning

confidence: 99%

Section: Car Nk Cellsmentioning

confidence: 99%

Section: Car Nk Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…To overcome CAR-T cell safety concerns, alternative killer immune cell subsets are currently being explored as CAR vessels. NK cells represent an appealing candidate population, as they are highly cytotoxic, but are not associated with GvHD, thereby showing higher potential for allogenic manufacturing [153,154]. A further ideal CAR vector for allogeneic therapy is represented by invariant natural killer T (iNKT) cells.…”

Section: Therapeutic Strategies To Restore Specific T Cell Immunosurv...mentioning

confidence: 99%

The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches

Lagreca

Riva²,

Nasillo³

et al. 2022

IJMS

View full text Add to dashboard Cite

Multiple Myeloma (MM) is a malignant growth of clonal plasma cells, typically arising from asymptomatic precursor conditions, namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). Profound immunological dysfunctions and cytokine deregulation are known to characterize the evolution of the disease, allowing immune escape and proliferation of neoplastic plasma cells. In the past decades, several studies have shown that the immune system can recognize MGUS and MM clonal cells, suggesting that anti-myeloma T cell immunity could be harnessed for therapeutic purposes. In line with this notion, chimeric antigen receptor T cell (CAR-T) therapy is emerging as a novel treatment in MM, especially in the relapsed/refractory disease setting. In this review, we focus on the pivotal contribution of T cell impairment in the immunopathogenesis of plasma cell dyscrasias and, in particular, in the disease progression from MGUS to SMM and MM, highlighting the potentials of T cell-based immunotherapeutic approaches in these settings.

show abstract

“…Moreover, the NG2/CSPG4 antigen may provide the basis for the selection of maximally potent, BiTE-redirected immune cells that may be candidates for the development of a novel immunotherapeutic strategy for solid organ cancers; for example, this antigen may be useful for chimeric antigen receptor (CAR) T-cell selection [ 72 , 73 , 74 ]. Genetic engineering technologies can redirect T lymphocytes, such as CD8 + cytotoxic T lymphocytes (CTLs), to recognize or target a wide variety of cancer antigens via the expression of a CAR [ 75 ].…”

Section: Selection Of Ng2/cspg4 As a Target Antigen For The Treatment...mentioning

confidence: 99%

Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers

Zhang

et al. 2022

Vaccines

View full text Add to dashboard Cite

: Neuro-glia antigen 2/chondroitin sulfate proteoglycan 4 (NG2/CSPG4, also called MCSP, HMW-MAA, MSK16, MCSPG, MEL-CSPG, or gp240) is a large cell-surface antigen and an unusual cell membrane integral glycoprotein frequently expressed on undifferentiated precursor cells in multiple solid organ cancers, including cancers of the liver, pancreas, lungs, and kidneys. It is a valuable molecule involved in cancer cell adhesion, invasion, spreading, angiogenesis, complement inhibition, and signaling. Although the biological significance underlying NG2/CSPG4 proteoglycan involvement in cancer progression needs to be better defined, based on the current evidence, NG2/CSPG4+ cells, such as pericytes (PCs, NG2+/CD146+/PDGFR-β+) and cancer stem cells (CSCs), are closely associated with the liver malignancy, hepatocellular carcinoma (HCC), pancreatic malignancy, and pancreatic ductal adenocarcinoma (PDAC) as well as poor prognoses. Importantly, with a unique method, we successfully purified NG2/CSPG4-expressing cells from human HCC and PDAC vasculature tissue blocks (by core needle biopsy). The cells appeared to be spheres that stably expanded in cultures. As such, these cells have the potential to be used as sources of target antigens. Herein, we provide new information on the possibilities of frequently selecting NG2/CSPG4 as a solid organ cancer biomarker or exploiting expressing cells such as CSCs, or the PG/chondroitin sulfate chain of NG2/CSPG4 on the cell membrane as specific antigens for the development of antibody- and vaccine-based immunotherapeutic approaches to treat these cancers.

show abstract

Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages

Cited by 31 publications

References 144 publications

Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer

Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer

The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches

Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers

Contact Info

Product

Resources

About